The neuroendocrine markers assay and the glycemia profile in patients with neuroendocrine tumors under octreotide therapy: a 2 years study / Determinarea markerilor neuroendocrini şi a profilului glicemic la pacienţii cu tumori neuroendocrine în tratament cu octreotid

1. Barakat MT, Meeran L, Bloom SR. Neuroendocrine tumors. Endocr Relat Cancer. 2004 Mar;11(1):1-18. DOI: 10.1677/erc.0.011000110.1677/erc.0.0110001Search in Google Scholar

2. Oberndorfer S. Karzinoide tumoren des dunndarms. Frank Z Pathol. 1907;1:426-432.Search in Google Scholar

3. Salazar R, Wiedenmann B, Rindi G, Ruszniewski P. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. Neuroendocrinology. 2012;95(2):71-3. DOI: 10.1159/00033560010.1159/000335600Search in Google Scholar

4. Pinchot S, Holen K, Sippel R, Chen H. Carcinoid Tumors. Oncologist. 2008;13(12):1255-1269. DOI: 10.1634/theoncologist.2008-020710.1634/theoncologist.2008-0207Search in Google Scholar

5. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol. 2013 Sep;20(5):285-314. DOI: 10.1097/ PAP.0b013e3182a2dc6710.1097/PAP.0b013e3182a2dc67Search in Google Scholar

6. Fisher-Colbrie R, Hagn C, Schober M. Chromogranins A, B, C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci. 1987;493:120-34. DOI: 10.1111/ j.1749-6632.1987.tb27189.x10.1111/j.1749-6632.1987.tb27189.xSearch in Google Scholar

7. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86(5):858-865. DOI: 10.1002/ (SICI)1097-0142(19990901)86:5<858::AID-CNCR23> 3.0.CO;2-810.1002/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8Search in Google Scholar

8. Iacangelo AL, Eiden LE. Chromogranin A: current status as a precursor for bioactive peptide and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept. 1995 Aug 22;58(3):65-88. DOI: 10.1016/0167-0115(95)00069-N10.1016/0167-0115(95)00069-NSearch in Google Scholar

9. Poiană C, Neamţu MC, Avramescu ET, Carşote M, Trifănescu R, Terzea D, et al. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol. 2013;54(3 Suppl):717-20.Search in Google Scholar

10. Poiană C, Neamţu MC, Avramescu ET, Carşote M, Trifănescu R, Terzea D, et al. The dedifferentiation of neuroendocrine tumor metastases: myth or reality? Rom J Morphol Embryol. 2013;54(1):201-3.Search in Google Scholar

11. Groth CM, Banzon ER. Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med. 2013 Aug;45(2):194-8. DOI: 10.1016/j. jemermed.2012.11.099Search in Google Scholar

12. Vinik Al, Silva MP, Woltering EA, Go VL, Warner R, Caplin M. Biochemical testing for neuroendocrine tumors. Pancreas. 2009;38(8):876-89. DOI: 10.1097/ MPA.0b013e3181bc0e7710.1097/MPA.0b013e3181bc0e77Search in Google Scholar

13. Lawrence B, Gustafsson Bl, Kidd M, Pavel M, Svejda B, Modlin M. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40(1):111-34. DOI: 10.1016/j.ecl.2010.12.00110.1016/j.ecl.2010.12.001Search in Google Scholar

14. Poiană C, Carşote M, Neamtu MC, Avramescu ET, Vasilescu F, Terzea D, et al. Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Rom J Morphol Embryol. 2013;54(4):1169-71.Search in Google Scholar

15. Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol. 1991;30(4):503-7. DOI: 10.3109/0284186910909240910.3109/02841869109092409Search in Google Scholar

16. Panzuto F, Di Fonzo M, Iannicelli E, Sciuto R, Maini CL, Capurso G, et al. Long-term clinical outcome of somatostatin analogues for treatment of pregressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. 2006;17(3):461-6. DOI: 10.1093/annonc/mdj11310.1093/annonc/mdj11316364959Search in Google Scholar

17. Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer. 2006;13(4):1213-21. DOI: 10.1677/ erc.1.0120010.1677/erc.1.0120017158766Search in Google Scholar